Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

properties of the s-EH inhibitors to the stage where we could present a convincing picture to venture groups of compounds ready to move to the clinic."

In 2005, the company raised more than $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures.

Today, the biotech company, based in Hayward, is dedicated to the discovery and development of novel drugs to treat type 2 diabetes, hypertension and inflammatory disorders, Hammock said. It is billed as the "world's leading company focused on s-EH, an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology."

"Our main goal," Hammock said, "was to set up a system of a science-driven company where we reduce the cost of drug registration by using very good incisive science. We also want to reward and motivate the people who do the work; provide a funding and training environment to help teach students and postgraduates to write proposals; and allow scientists to move between an academic and industrial environment in the early stage to help determine career directions."

Another goal: a low-cost, affordable drug. "The sickest people in the world, of course, cannot pay for the drugs they need," Hammock said. "The chemistry developed around the s-EH inhibitors allows us to make powerful but inexpensive drugs that could be produced in developing countries."

Meanwhile, the clinical trials under way represent two firsts, said James Sabry, president and chief executive officer of Arte Therapeutics. "This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension."

."AR9281 has demonstrated an excellent
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:1/22/2015)... YORK , Jan. 22, 2015   EyeLock, Inc. , ... it has appointed Steve Gerber to the new ... will be responsible for leading development of mobile platforms and ... years of success and innovation in the semiconductor industry to ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... UT Southwestern neuroscience researchers have identified a gene that controls ... mice often used to study addiction and behavior patterns. ... , determines how mammals respond to cocaine, although it is ... or for addiction, said Dr. Joseph Takahashi , chair ...
... Department of Energy,s Brookhaven National Laboratory have identified a ... class of plant products with a wide range of ... source of flavors, fragrances, and pigments; some are of ... contribution to the construction of plant cell walls, (poly)phenols ...
... of superstars in the materials world. Already prized for ... identity, vanadium dioxide can now add muscle power to ... Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... from vanadium dioxide that for its size is a ...
Cached Biology News:UT Southwestern neuroscience researchers identify gene involved in response to cocaine 2Enlisting cells' protein recycling machinery to regulate plant products 2A micro-muscular breakthrough 2A micro-muscular breakthrough 3
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Approval of Genasense in Relapsed/Refractory Patients, BERKELEY ... GNTA ) announced that the Company has completed ... Janet Woodcock, Acting,Director of the Center for Drug ... Administration (FDA). The appeal asks that CDER approve ...
... Cell,Genesys, Inc. (Nasdaq: CEGE ), today announced ... and Sharon E. Tetlow, senior,vice president and chief financial ... to the company,s third quarter financial results,that will be ... at 2:00 p.m. PT/ 5:00 p.m. ET. The ...
... Include World-Renowned RNase and RNA Researchers, SOMERSET, ... of ribonuclease (RNase) therapeutics will be the focus ... by Alfacell,Corporation (Nasdaq: ACEL ). Moderated ... officer, and David Sidransky, M.D., Alfacell,s scientific,advisory board ...
Cached Biology Technology:Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4
... The wide mini ReadySub-Cell GT cell and PowerPac ... gel electrophoresis of nucleic acids in agarose gels. ... tank, lid with cables and electrodes, and leveling ... 220-240 V, provides output of 10-300 V, 4-400 ...
... Simplify the process and you reduce ... built into the CEQ 8000. Developed using ... and leadership in capillary electrophoresis technology, the ... analysis system. This system automatically fills the ...
... Capillary Electrophoresis System uses revolutionary technology ... (SPE), urine protein electrophoresis and immunofixation/subtraction ... analysis. The system is truly automated, ... no staining to process patient samples. ...
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
Biology Products: